SALT LAKE CITY - Recursion, a clinical-stage TechBio company listed on Nasdaq (NASDAQ: RXRX), announced the appointment of Najat Khan, PhD, as its new Chief R&D Officer and Chief Commercial Officer.
Dr. Khan, who previously served as the Chief Data Science Officer and Global Head of Strategy and Portfolio at Johnson & Johnson's Innovative Medicine R&D, will also join Recursion's Board of Directors.
Dr. Khan brings a wealth of experience from her tenure at Johnson & Johnson, where she played a pivotal role in building an industry-leading pipeline of transformational medicines. Her expertise spans across biological, chemical, and medical sciences, as well as data science and business leadership. She has been instrumental in driving the impact of data science and AI on a large scale and has established a top-tier diverse data science team.
In her new role at Recursion, Dr. Khan will lead the company's research and development efforts and spearhead the development of its commercial capabilities. Chris Gibson, Co-Founder and CEO of Recursion, expressed enthusiasm for Dr. Khan's vision and passion for transforming drug discovery and development, which aligns with Recursion's mission.
Dr. Khan's appointment comes as Recursion continues to leverage its proprietary platform, the Recursion OS, to decode biology and industrialize drug discovery. The platform, which employs machine-learning algorithms, aids in the expansion of one of the world's largest proprietary biological, chemical, and patient-centric datasets.
Apart from her professional achievements, Dr. Khan is actively involved in the broader scientific community. She serves as a board member for the Alliance for Artificial Intelligence in Healthcare and is a Steering Committee member of the White House's Moonshot CancerX program. She also co-chairs the Data Science in Industry Roundtable (DISRUPT).
Dean Li, Co-Founder and Board Member of Recursion and President of Merck Research Laboratories, welcomed Dr. Khan to the board, noting her valuable insights as the company enters the era of AI-enabled drug discovery and development.
This announcement is based on a press release statement.
InvestingPro Insights
As Recursion (NASDAQ: RXRX) welcomes Dr. Najat Khan to its executive team, the company's financial health and market performance provide a backdrop to the strategic appointment. With a market capitalization of approximately $1.83 billion, the company holds a significant position in the biotech sector. Notably, Recursion has more cash than debt on its balance sheet, indicating a solid liquidity position that could support its ambitious R&D efforts under Dr. Khan's leadership.
The company's stock has experienced a high return over the last year, with a 51.52% increase in price total return, reflecting investor confidence in its growth potential and technological capabilities. Moreover, Recursion's liquid assets exceed its short-term obligations, further emphasizing its financial stability as it continues to invest in drug discovery and AI integration.
Investors should note, however, that the stock's recent performance has been less robust, with a 19.79% decline over the last month. This volatility may present opportunities for those looking to invest in a company at the forefront of AI-driven biotechnology, especially as the company does not pay dividends, focusing instead on reinvesting in its core business.
For more in-depth analysis and additional InvestingPro Tips, such as the fact that analysts do not anticipate the company will be profitable this year and the RSI suggests the stock is in oversold territory, visit InvestingPro. Recursion currently has 11 more tips listed on InvestingPro, offering a comprehensive view of the company's financial and market performance.
Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking valuable insights that could inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.